Collaboration with Grünenthal

May 4, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Grünenthal, a pharmaceutical company headquartered in Aachen in Germany, on a series of clinical single-cell based proteomics projects.

Read more >
Read more

Collaboration with Frame Cancer Therapeutics

April 26, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Frame Cancer Therapeutics, an Amsterdam pharmaceutical company,  on a series of clinical proteomics projects.

Read more >
Read more

Collaboration with Ludwig Cancer Research.

April 21, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Ludwig Cancer Research Center on a series of clinical proteomics projects.

Read more >
Read more

Collaboration with Hemogenyx Pharmaceuticals.

April 15, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Hemogenyx Pharmaceuticals on a series of clinical proteomics projects.

Read more >
Read more

Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media

Complete Omics’ Clinical Proteomics team is proud to share with you the recent media coverage of our efforts in paving the way for the ultimate personalized cancer therapeutics. Our efforts toward achieving this ultimate goal of cancer treatment were reported by GenomeWeb, The Scientist, Precision Oncology News, News Wise, Fierce Biotech, etc. One of our clinical proteomics pipelines can help identify personalized cancer neoantigens that can be further targeted by a variety of therapeutic approaches, such as mRNA cancer vaccine, therapeutic peptide injection, engineering cell therapy, and here two bispecific antibody approaches.

Read more >
Read more

Complete Omics published novel technologies on SCIENCE and SCIENCE IMMUNOLOGY.

Complete Omics Inc. (official website) – For years, personalized cancer therapeutics has been an ultimate goal for all cancer patients and doctors. Healthcare providers and scientists working across the biopharmaceutical industry have been tirelessly committed to bringing to patients more and more, better and better, personalized cancer therapeutic approaches.

Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer diagnostics and treatment through our multi-omics platform that we have published on Science Immunology and Science.

Read more >
Read more

Collaboration with Drs. Bai and Staedtke in JHH

Feb 10, 2021 | BALTIMORE –  Complete Omics’ Clinical Metabolomics team announced a collaboration with Dr. Renyuan Bai and Dr.  in Johns Hopkins Medicine on a series of metabolomics targeted detection projects.

Read more >
Read more

Congratulations to our lab alumni founders in Thrive Earlier Detection.

NEW YORK – Exact Sciences has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection, a molecular diagnostics company founded by Vogelstein lab trainees from Johns Hopkins, for cash and stock consideration of up to $2.15 billion.

Read more >
Read more

Collaboration with MD Anderson

Aug 19, 2020 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with MD Anderson on a variety of molecular diagnostics projects.

Read more >
Read more

Collaboration with MSKCC

Mar 29, 2020 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with, MSKCC, a world leader in cancer care on a variety of molecular diagnostics projects.

Read more >
Read more
Follow by Email
Facebook
Twitter
LinkedIn